Citius Pharma Q2 Net Loss $37.5M; $5.6M Revenue; Going Concern Doubt
Citius Pharmaceuticals reported a net loss of $37.5 million for the six months ended March 31, 2026, an increase from $21.8 million in the prior year, despite generating $5.6 million in revenue from LYMPHIR sales. The company's operating expenses significantly rose to $45.7 million, and it experienced increased cash burn from operations. Management expressed substantial doubt about the company's ability to continue as a going concern beyond November 2026, though recent capital raises by Citius Pharma and its subsidiary Citius Oncology are expected to extend its cash runway.
Key Highlights
- Six-month net loss was $37.5 million, up from $21.8 million year-over-year.
- Generated $5.6 million in revenue from LYMPHIR sales for the six months.
- Operating expenses rose to $45.7 million from $21.3 million year-over-year.
- Net cash used in operations increased to $14.3 million from $9.3 million year-over-year.
- Company faces substantial doubt about going concern beyond November 2026.
- Post-period, Citius Pharma raised $5.0 million via direct offering.
- Citius Oncology raised $11.5 million from warrant exercise and secured a $25.0 million loan.
- Net loss per share was $(1.34) for the six months, compared to $(2.58) prior year.
Price Impact
More from CTXR
Citius Oncology Presents Positive Quality of Life Data for LYMPHIR®
Citius Oncology Presents Promising Phase 1 Data for LYMPHIR in Gynecologic Cancers
Citius Pharma Q2 Net Loss $(21.2)M; LYMPHIR Revenue $1.7M; Secures $41.5M Financing